Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 4,076 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: stem cells Clear all

Conditions: Leukemia, Lymphoid, Leukemia, Myeloid, Myelodysplastic Syndromes, Myelofibrosis, Lymphoma, Malignant, Multiple Myeloma, Waldenstrom Macroglobulinemia
Interventions: Fludarabine, Busulfan, Rabbit ATG, Methotrexate; Drug · Biological
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Bone Marrow Failure Disorders, Aplastic Anemia, Thrombocytopenia, Refractory Cytopenia of Childhood, Myelodysplastic Syndrome(MDS)
Interventions: Romiplostim; Drug
Lead sponsor: Anjali Sharathkumar; Other
Eligibility: 0 Years to 21 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions: Fludarabine Phosphate, Tacrolimus, Thiotepa, Total-Body Irradiation (TBI), Magnetic Affinity Cell Sorting, Peripheral Blood Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, T Cell-Depleted Hematopoietic Stem Cell Transplantation; Drug · Radiation · Other + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 14 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 2
States / cities: New Haven, Connecticut • Seattle, Washington

Conditions: Hematopoietic Stem Cell Transplant
Interventions: Music Therapy, No Music Therapy; Behavioral
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Immunosuppression, Leukemia
Interventions: SOLEX 300i Stem Cell Selection; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 10 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Wound of Skin
Interventions: The Celution System; Device
Lead sponsor: Winthrop University Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Polycystic Ovary Syndrome (PCOS), Polycystic Ovary Syndrome, PCOS
Interventions: Cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells; Biological
Lead sponsor: The Foundation for Orthopaedics and Regenerative Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Naples, Florida

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: 6 Minute Walk Functional Test, Behavioral Intervention, Survey Administration, Timed Get Up and Go Test; Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 6 Years to 29 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 2
States / cities: Dallas, Texas • Houston, Texas

Conditions: Cancer
Interventions: infection prophylaxis and management; Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 12 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2002
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Ovarian Cancer
Interventions: mitoxantrone hydrochloride, thiotepa, topotecan hydrochloride, peripheral blood stem cell transplantation; Drug · Procedure
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hematopoietic Neoplasm
Interventions: Dietary intake -Food Frequency Questionnaire, Receptivity to Participating in Diet Interventions; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Transplant-Related Disorder, GVH - Graft Versus Host Reaction
Interventions: CliniMACS® CD34 TCR Alpha/Beta; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: Up to 21 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
Interventions: autologous tumor cell vaccine, peripheral blood lymphocyte therapy; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Solid Organ Transplant Rejection, Organ Rejection Transplants, Organ Rejection
Interventions: ExoFlo; Biological
Lead sponsor: Direct Biologics, LLC; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Palo Alto, California • San Francisco, California

Conditions: Hematological Malignancies
Interventions: Cyclophosphamide, Thiotepa, Fludarabine, Melphalan, Mesna, G-CSF, Mycophenolate mofetil, Tacrolimus, Methylprednisolone, Total lymphoid irradiation, Lymphocyte infusions, CliniMACS; Drug · Biological · Radiation + 1 more
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Graft-versus-Host Disease
Interventions: Lenalidomide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
Interventions: Ifosfamide, Etoposide, Mesna, G-CSF, Busulfan, Melphalan, Thiotepa, Autologous stem cell infusion, Radiation, Carboplatin, Paclitaxel, Leukapheresis, Anti-seizure prophylaxis, Ursodiol; Drug · Biological · Radiation + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cytomegalovirus Infections
Interventions: Ganciclovir; Drug
Lead sponsor: New York Medical College; Other
Eligibility: Up to 26 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Obesity, Morbid
Interventions: Bariatric Surgery, Anti Obesity Drugs; Procedure · Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 90 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Lymphoid Leukemia
Interventions: Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR), Treg CD34+HSPC (Orca-T); Drug
Lead sponsor: Melody Smith; Other
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2045
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Multiple Myeloma, Myeloma
Interventions: FT576 (Allogenic CAR NK cells with BCMA expression), Cyclophosphamide, Fludarabine, Daratumumab, Bendamustine; Drug
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 14
States / cities: Birmingham, Alabama • Duarte, California • Denver, Colorado + 11 more

Conditions: Breast Cancer
Interventions: anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, melphalan, methotrexate, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: La Jolla, California

Conditions: SCI - Spinal Cord Injury, SCI, Spinal Cord Injury
Interventions: Human allogeneic, culture expanded, UC-MSC; Drug
Lead sponsor: Cell Therapy LLC; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: Palonosetron, ondansetron, Dexamethasone; Drug
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: 18 Years to 85 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG

TPO-Mimetic Use in Children for Hematopoietic Failure

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

Music Therapy and Hematopoietic Stem Cell Transplant

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances

Adipose-derived Stem Cells to Treat Chronic Wounds.

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for PCOS

Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant

Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer

UF-BMT-HSCT-001: A Non-Interventional Study Evaluating Diet in HSCT Survivors

Treatment Use of the CliniMACS® CD34 TCR Alpha/Beta for Allogenic Transplant (Expanded Access Use)

Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant

Expanded Access for Use of ExoFlo in Abdominal Solid Organ Transplant Patients

Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen

Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients

Modeling the Neurological Basis and Characterizing the Neurological Phenotype of Obesity Using Human Neural Stem Cells

Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL

FT576 in Subjects With Multiple Myeloma

Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer

NeuroRise: Intrathecal CE-1 Treatment for Traumatic SCI

Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients